
|Videos|June 27, 2022
Dr. Zhang on frontline treatment selection factors in metastatic kidney cancer
Author(s)Urology Times staff
“We use a lot of clinical characteristics, but I’m hopeful we will start to go into more molecular typing and gene signatures,” says Tian Zhang, MD.
Advertisement
Tian Zhang, MD, associate professor at UT Southwestern Medical Center, discusses factors she uses in the clinic to decide among the evolving treatment options in the frontline setting for patients with metastatic renal cell carcinoma.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC
2
Testosterone deficiency: FAQs from the AUA guideline
3
Joshua Lang, MD, MS, on integrating molecular biomarkers into clinical practice
4
Large registry study reports durable 10-year outcomes with focal therapy for prostate cancer
5












